Skip to content

CHARITÉ™ Artificial Disc Compared to Anterior Interbody Fusion for Treatment of Degenerative Disc Disease

Clinical Investigation of the SB Charite III Intervertebral Disc Spacer.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00215306
Enrollment
304
Registered
2005-09-22
Start date
2000-03-31
Completion date
2004-03-31
Last updated
2014-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative Disc Disease

Keywords

arthroplasty, lumbar, spine

Brief summary

The study is designed to evaluate the safety and effectiveness of the CHARITE Artificial Disc compared to anterior lumbar interbody fusion for treatment of degenerative disc disease at one level of the lumbar spine (either L4/L5 or L5/S1).

Detailed description

Treatments for disc degeneration have historically included conservative modalities, such as rest, heat, electrotherapy, physical therapy, and analgesics to surgery. Currently, there are two main surgical techniques for treatment of disc degeneration: (1) nucleotomy or diskectomy, i.e., excision of part or all of the degenerated disc, which is typically performed for treatment of radicular syndrome in the case of disc herniation; and (2) spinal fusion, i.e., grafting bone between the vertebrae adjacent to the degenerated disc to eliminate articulation at the damaged segment, which is typically performed for treatment of degeneration together with instability and reduction of the intervertebral space. Rigid internal fixation may also be used to promote fusion. The CHARITÉ Artificial Disc is designed to provide a new therapeutic option for treatment of degenerative disc disease as an alternative to spinal fusion to preserve function in the lumbar vertebral region. Each institution participating in the study was to treat the first 5 consecutive study participants with the CHARITE to as it involves a modification to the technique used for anterior fusion. Data will be collected on these training cases but will not be included in the comparison with the control (fusion) treatment. Comparison: Outcomes for patients treated with the CHARITÉ Artificial Disc will be compared to outcomes for patients treated with anterior lumbar interbody fusion.

Interventions

DEVICECHARITÉ Artificial Disc
DEVICEAnterior Interbody Fusion with BAK Cage

Sponsors

DePuy Spine
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* 18 to 60 years of age inclusive * symptomatic degenerative disc disease confirmed by provocative discogram * single level disease L4/L5 or L5/S1 * leg or back pain without nerve root compression * VAS pain score \>= 40 * Oswestry Disability Index score \>= 30 * six months prior conservative treatment * appropriate for anterior surgical approach

Exclusion criteria

* previous lumbar or thoracic fusion * other spinal surgery at target level * symptomatic multiple level degeneration * non-contained or extruded nucleus pulposus * compression or burst at L4, L5, or S1 due to trauma * mid-sagittal stenosis \< 8mm * osteoporosis, osteopenia, or other metabolic bone disease of the spine * spondylolisthesis \> 3mm, scoliosis \> 11 degrees * facet joint arthrosis * isthmic spondylolisthesis * positive straight leg raise for radiculopathy

Design outcomes

Primary

MeasureTime frame
Pain and Function (Oswestry Disability Index)
Neurologic Function
Major Adverse Events
Subsequent Surgical Interventions

Secondary

MeasureTime frame
Fusion (control only)
Angular Range of Motion
Adverse Events
Work Status
Patient Satisfaction
Duration of Hospitalization
Back and Leg Pain (VAS)
SF-36; Health Related Quality of Life
Disc Space Height

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026